Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heterospirone n-phenylindole compound, its preparation method and application

A technology of phenylindole compound and heterospiroketone, which can be applied in the field of medicinal chemistry and can solve problems such as metabolic instability

Active Publication Date: 2015-09-30
陈志龙
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in clinical practice, it is limited due to oral ineffectiveness, unstable metabolism, and partial AngII agonism
In 1982, when Japan's Takeda Pharmaceutical Company was studying the diuretic and antihypertensive effects of imidazole acetic acid compounds, it first discovered that S-8307 could inhibit the Ang II-induced rabbit arterial contraction and boosting effect. Although the activity is weak, it belongs to the Ang II receptor Specific antagonist without the agonistic effect of Saralasin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterospirone n-phenylindole compound, its preparation method and application
  • Heterospirone n-phenylindole compound, its preparation method and application
  • Heterospirone n-phenylindole compound, its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The compound: 2-butyl-3-[[1-[2-(1H-tetrazol-5-yl)phenyl]-1H-indol-4-yl]methyl]-1,3-di The preparation method of azaspiro[4,4]non-1-en-4-one (compound Ib) specifically comprises the following steps:

[0025]

[0026] Step 1: Synthesis of 2-butyl-3-[(1-benzoyl-1H-indol-4-yl)methyl]-1,3-diazaspiro[4,4]non-1-ene -4-ketone (compound Ib 3 )

[0027] Butyl heterospirone (compound Ib 1 ) was prepared by referring to literature (J Med Chem, 1993, 36: 4230-4238). (4-(bromomethyl)-1H-indol-1-yl)(phenyl)methyl ketone (compound Ib 2 ) was prepared with reference to literature (J Med Chem, 1993, 36, 3371-3380). Butylheterospirone (800 mg, 3.48 mmol) and 60% NaH (293 mg, 7.33 mmol) were dissolved in 15 mL of anhydrous THF. Under nitrogen protection, stir at 50 °C for 30 min. After cooling to room temperature, 10 mL of anhydrous THF solution containing (4-(bromomethyl)-1H-indol-1-yl)(phenyl)methyl ketone (1000 mg, 3.18 mmol) was slowly added dropwise. Then heated and stirred...

Embodiment 2

[0035] 2-Propyl-3-[[1-[2-(1H-tetrazol-5-yl)phenyl]-1H-indol-4-yl]methyl]-1,3-diazaspiro The preparation method of cyclo[4,4] non-1-en-4-one (I a):

[0036] The experimental procedure is as described in Example 1, and the yield is 46.7%. 1 HNMR (400MHz, CDCl 3 )δ: 8.20 (1H, m, N-CH), 7.59-6.70 (7H, m, Ph-H), 6.54 (1H, m, CH=C), 4.91 (2H, s, N-CH 2 ), 2.25-2.22 (2H, t, J=7.2Hz, C H 2 CH 2 CH 3 ), 1.86 (8H, m, CH 2 CH 2 CH 2 CH 2 ), 1.49 (2H, m, C H 2 CH 3 ), 0.85-0.81 (3H, t, J=7.2HZ, -CH3); MS (ESI) m / z 454.5 [M+1] +

Embodiment 3

[0038] 2-Propyl-3-[[1-[2-(1H-tetrazol-5-yl)phenyl]-1H-indol-5-yl]methyl]-1,3-diazaspiro The preparation method of cyclo[4,4]non-1-en-4-one (IIa):

[0039] The experimental procedure is as described in Example 1, and the yield is 45.9%. 1 HNMR (400MHz, CDCl 3 )δ: 8.05 (1H, m, N-CH), 7.59-6.70 (7H, m, ph-H), 6.54 (1H, m, CH=C), 4.91 (2H, s, N-CH 2 ), 2.25-2.22 (2H, t, J=7.2Hz, C H 2 CH 2 CH 3 ), 1.96 (8H, m, CH 2 CH 2 CH 2 CH 2 ), 1.59 (2H, m, C H 2 CH3 ), 0.85-0.81 (3H, t, J=7.2Hz, -CH3); MS (ESI) m / z: 454.5 [M+1] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a spiro heterocyclic ketone N-phenyl indole compound, its preparation method and application in controlling cardiovascular diseases and other medicine fields. The compound is formed by organically connecting spiro heterocycle, indole, phenyl ring and tetrazole, is an AT1 type acceptor retarding agent of angiotensin II, and can be used for preventing or treating hypertension, coronary heart disease, disease in blood vessels of heart, brain and kidney, hemicrania, pulmonary hypertension and other diseases.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to a class of medicines for the prevention and treatment of hypertension, other cardiovascular and cerebrovascular diseases, migraine, pulmonary hypertension and other diseases. Background technique [0002] The renin-angiotensin system (RAS) is an important factor in the regulation of blood pressure and electrolyte balance. Angiotensinogen secreted by the liver is converted into angiotensin I (Ang I) under the action of renin. Ang I generates angiotensin II (AngII) under the action of angiotensin-converting enzyme (ACE). AngII receptors mainly include AngII type 1 receptors (AT 1 receptor), Ang II type 2 receptor (AT 2 receptor) two receptor subtypes. At present, it is believed that the physiological function of AngII is mainly caused by AT 1 receptor mediated. When AngII and AT 1 When the receptor acts, it leads to the strengthening of cardiovascular contraction, the hype...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D403/14A61K31/4184A61P9/12A61P9/10A61P9/00A61P25/06
Inventor 陈志龙袁伟东达雅静乜永艳郄骊李福民叶颖
Owner 陈志龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products